ARTICLE | Emerging Company Profile
Mirai: One-stop shop for genetic medicine developers
With $50M from Flagship, Mirai is optimizing nucleic acid design, delivery and manufacturing for clients
January 4, 2025 12:59 AM UTC
Launched in September with $50 million from Flagship, Mirai has put nucleic acid design, delivery and manufacturing under one roof so that its biotech partners can focus on validating the biology behind their nucleic acid therapies rather than the logistics of making them.
“I think it’s safe to say that in 2040, if you were to look at the top 10 drugs, there will be a number of nucleic acid medicines on that list. Mirai is betting on that,” Founding President and Flagship Pioneering Operating Partner Hari Pujar told BioCentury...